Reid Hoffman Steps Away From Microsoft After a Decade
One of Silicon Valley's most recognizable names is making a major career pivot. Reid Hoffman, the co-founder of LinkedIn and longtime venture capitalist, is leaving Microsoft's board of directors to dedicate himself entirely to Manus, his AI-driven drug discovery startup.
Hoffman announced the move this week, describing his decision as a return to "founder mode" — a phrase popularized in tech circles to describe the hands-on, deeply involved leadership style of company founders versus professional managers. After spending more than ten years as a Microsoft board member, a tenure that proved extraordinarily lucrative given the company's explosive growth during that period, Hoffman is betting his next chapter on the convergence of artificial intelligence and medicine.
What Is Manus?
Manus is an AI startup focused on drug discovery — using machine learning and large-scale data modeling to accelerate the notoriously slow and expensive process of finding new medicines. The pharmaceutical industry has long struggled with sky-high failure rates in clinical trials and development timelines that can stretch across decades. AI-powered platforms like Manus aim to dramatically compress that process by identifying promising drug candidates faster and with greater precision than traditional methods allow.
The space has attracted enormous investment and talent in recent years. Companies like Isomorphic Labs (backed by Google DeepMind), Recursion Pharmaceuticals, and Insilico Medicine are all racing to prove that AI can fundamentally transform how drugs are developed. Hoffman's entry into this field — with his track record of backing transformative companies like PayPal, Facebook, and Airbnb — signals just how serious the sector has become.
A Profitable Decade at Microsoft
Hoffman's tenure on Microsoft's board coincided with one of the most remarkable corporate turnarounds in tech history. Under CEO Satya Nadella, Microsoft pivoted aggressively toward cloud computing with Azure, made a landmark investment in OpenAI, and saw its market capitalization soar into the trillions. Hoffman, who was already a close ally of OpenAI's leadership through his venture firm Greylock Partners, was well-positioned at the intersection of those worlds.
His departure from the board is unlikely to unsettle Microsoft — the company has deep leadership in place and its AI strategy is well underway. But it does mark the end of a significant era for one of the tech industry's most influential board members.
Why Now?
Hoffman has been increasingly vocal about the transformative potential of AI across every sector, but healthcare appears to be where he sees the biggest opportunity — and perhaps the biggest responsibility. Drug discovery powered by AI isn't just a business bet; it's a chance to address some of humanity's most persistent challenges, from cancer to antibiotic resistance to rare diseases that have never had viable treatments.
By going all-in on Manus, Hoffman is signaling that the moment for AI in medicine has arrived — and that he wants to be at the centre of it, not watching from a boardroom.
Whether Manus can deliver on that promise remains to be seen. But with Hoffman fully committed and the broader AI healthcare sector booming, the startup is certainly stepping into the spotlight at the right time.
Source: TechCrunch